Last reviewed · How we verify
Ty21a
Ty21a, developed by the University of Oxford, is a marketed vaccine with a key composition patent expiring in 2028. The primary strength of Ty21a lies in its established market presence and long-term use. The primary risk is the potential increase in competition following the patent expiry in 2028.
At a glance
| Generic name | Ty21a |
|---|---|
| Also known as | Vivotif |
| Sponsor | University of Oxford |
| Modality | Biologic |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Blood Donor CVD 5000 (PHASE4)
- CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults (PHASE4)
- WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study (EARLY_PHASE1)
- Induction of Gut Permeability by an Oral Vaccine (EARLY_PHASE1)
- NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors (PHASE1)
- CVD 38000: Study of Responses to Vaccination With Typhoid and/or Cholera (PHASE4)
- Effects of Aging on Primary and Secondary Vaccine Responses (PHASE1)
- Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ty21a CI brief — competitive landscape report
- Ty21a updates RSS · CI watch RSS
- University of Oxford portfolio CI